课题基金 / 基金详情

项目摘要

项目成果

Steven R. Grossman的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):P53肿瘤抑制因子通过激活生长抑制或凋亡程序来对抗广泛的压力,包括化学诱变剂、电离辐射、低氧和营养缺乏。所有癌症都必须在其一个或多个节点上使P53网络失活才能进展。最常见的情况是,p53发生突变,使其在肿瘤中失活。在其他情况下,p53的调节因子是改变的,而不是p53本身。通常,癌细胞中改变的调节因子参与泛素/蛋白酶体系统对P53蛋白的正常破坏。泛素/蛋白酶体系统对P53的破坏是一个复杂的过程,涉及单泛素化、多泛素化、多泛素结合蛋白的识别以及蛋白酶体的识别和降解。P53是由E3连接酶MDM2单素化的,先前的研究表明,p300/CBP共激活子是E4酶,催化细胞质中P53的进一步多泛素化。多泛素化的p53可以被hHR23家族的蛋白酶体适配器蛋白识别,这些蛋白似乎可以保护p53免受细胞应激后蛋白酶体的破坏,如DNA损伤,但也可能正常地将p53运送到蛋白酶体。反过来,hHR23蛋白被蛋白酶体的S5a亚基识别,这可能是P53蛋白酶体的门户,导致其破坏。这一新的应用的目的是:1.表征p300/CBP E4活性的P53多泛素化的结构和功能2.研究P300/CBP E4和Ub结合活性在P53调节中的作用3.研究hHR23和S5a在P53调节中的作用坚定和完整地理解P53被泛素/蛋白酶体系统破坏的途径将增加我们对如何通过破坏这一途径形成癌症的了解,也将导致针对这一途径的新癌症治疗的发展。这种疗法有望在那些携带野生型P53的肿瘤中重新激活P53,导致肿瘤内恶性细胞的停滞或凋亡。
英文摘要
DESCRIPTION (provided by applicant):The p53 tumor suppressor counters a wide range of stresses, including chemical mutagens, ionizing radiation, hypoxia, and nutrient deprivation, by activating growth arrest or apoptosis programs. All cancers must inactivate the p53 network at one or more of its nodes to progress. Most often, p53 is mutated such that it is inactivated in tumors. In other cases, regulators of p53 are altered instead of p53 itself. Frequently, the regulators that are altered in cancer cells participate in the normal destruction of p53 protein by the ubiquitin/proteasome system. The pathway of p53 destruction by the ubiquitin/proteasome system is complex, involving monoubiquitination, polyubiquitination, recognition by polyubiquitin-binding proteins, and recognition and degradation by the proteasome. p53 is monoubiquitinated by the E3 ligase MDM2, and work from the prior grant has shown that the p300/CBP coactivators are E4 enzymes catalyzing further polyubiquitination of p53 in the cytoplasm. Polyubiquitinated p53 can be recognized by the hHR23 family of proteasome adaptor proteins, which appear to shield p53 from proteasome destruction after cell stress such as DNA damage, but may also normally deliver p53 to the proteasome. hHR23 proteins, in turn, are recognized by the S5a subunit of the proteasome, which may be the gateway to the proteasome for p53, leading to its destruction. The Aims of this renewal application are to: 1. Characterize the structure and function for p53 polyubiquitination of a p300/CBP E4 activity 2. Investigate the role of p300/CBP E4 and Ub binding activities in p53 regulation 3. Investigate the role of hHR23 and S5a in p53 regulation A firm and complete understanding of the pathway of p53 destruction by the ubiquitin/proteasome system will increase our knowledge of how cancers form through disruption of this pathway, and also lead to the development of novel cancer therapeutics targeting this pathway. Such therapeutics hold the hope of reactivating p53 in those tumors harboring wild type p53, leading to the arrest or apoptosis of malignant cells within.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1177/1947601912455198
发表时间: 2012-03-01
期刊: Genes & cancer
影响因子: --
作者: [Love, Ian M, Grossman, Steven R]
通讯作者: Grossman, Steven R
The Role of p53-inducible Sesn1 and Sesn2 genes in lung carcinogenesis
  • 批准号:
    9198533
  • 项目类别:
  • 资助金额:
    $31.64万
  • 财政年份:
    2013
  • 负责人:
    Steven R. Grossman
  • 依托单位:
The Role of p53-inducible Sesn1 and Sesn2 genes in lung carcinogenesis
  • 批准号:
    8997468
  • 项目类别:
  • 资助金额:
    $31.64万
  • 财政年份:
    2013
  • 负责人:
    Steven R. Grossman
  • 依托单位:
Targeting the ARF/CtBP Axis in Pancreatic Cancer
Targeting the ARF/CtBP Axis in Pancreatic Cancer
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: